Study Highlights Heart Failure Prevention with Diabetic Drug

A recent study in Nature Medicine suggests that diabetic medications might reduce the risk of heart failure, especially for certain patients. Specifically, the SGLT2 inhibitor dapagliflozin, used for type 2 diabetes, shows promise in preventing heart failure among those with a rare genetic mutation linked to cardiomyopathy, a condition that progressively affects the heart muscle.

Researchers from prestigious institutions including Harvard Medical School and the Massachusetts Institute of Technology analyzed data from the DECLARE-TIMI 58 trial. The study encompassed over 12,000 adults diagnosed with type 2 diabetes who also faced heightened cardiovascular risks.

Of the participants, around 121 had inherited gene mutations that might increase their likelihood of developing cardiomyopathy. Following an average monitoring period of 4.2 years, the results indicated that dapagliflozin significantly lowered hospitalizations for heart failure in those with the mutation compared to those without.

Interestingly, while dapagliflozin reduced heart failure-related hospitalizations across the board, its impact was notably greater—about eight times stronger—among the genetic carriers. In another surprising detail, 12.8% of the 82% of carriers without a history of heart failure eventually experienced heart failure in the placebo group. However, none in the dapagliflozin group did.

Shinwan Kani, MD, a lead author on the study, noted that these findings could transform preventive care approaches. He highlighted a long-standing challenge: identifying genetic variants linked to cardiomyopathy usually left patients without clear preventative strategies. But this research shows that effective tools might be available to mitigate those risks.

Dr. Andrew Freeman, a cardiologist not involved in the study, praised the results as “encouraging” and emphasized the potential for a new era of heart failure prevention that is both more precise and informed by genetic data.

Despite the promising nature of the findings, experts stress the need for further confirmation, given the analysis is based on a large randomized trial with a limited number of carriers. Freeman pointed out that while dapagliflozin already benefits a broad spectrum of patients, including those with diabetes and chronic kidney disease, identifying particular subgroups who may benefit most could be a game changer.

Genetic testing remains a routine approach for diagnosing cardiomyopathy. Should future clinical trials reaffirm these findings, there could be a shift towards more proactive identification of high-risk patients. It may pave the way for early treatments, possibly preventing symptoms of heart failure before they manifest, such as shortness of breath or fluid retention.

Overall, as Freeman aptly states, medication choices should always be made in consultation with health professionals. This is particularly vital for individuals with personal or familial cardiovascular events.